MicroRNAs in abdominal aortic aneurysms

The abdominal aortic aneurysm (AAA), representing 70% to 90% of all aortic aneurysms, is characterized by a widening of the diameter due to an irreversible weakening of the vascular walls. Risk factors include advanced age, male sex, smoking, hypertension, atherosclerosis, and genetic predisposition. From a pathophysiological point of view, AAA involves alterations in connective tissue proteins, chronic inflammation with the release of cytokines and matrix metalloproteinases, as well as changes in the extracellular matrix. MicroRNAs (miRNAs) have emerged as promising biomarkers and therapeutic targets in the regulation of gene expression and different specific signaling pathways in vascular pathologies. Among which some miRNAs have been highlighted such as: miR-29 and miR-27b-3p, involved in the degradation of the extracellular matrix and inflammatory processes during the progression of AAA. Some diagnostic methods such as computed tomography play a fundamental role, while some innovative therapeutic strategies, such as the inhibition of miRNAs, represent a leading role as possible diagnostic and therapeutic targets. A comprehensive approach includes surveillance and surgical treatment strategies to mitigate the progression and risk of AAA rupture, thus highlighting the relevance of miRNAs in the diagnosis and treatment of this pathology.